11/19/2022 0 Comments Monal mehta![]() ![]() "Endeavor BioMedicines is developing precision medicines targeting the genetic culprits of cancer and fibrosis," said John Hood, Ph.D., Co-Founder, CEO and Chairman of Endeavor BioMedicines."Researchers have investigated Hedgehog and ULK1 signaling pathways over the last decade, but now we have the understanding and capability to identify the patients who will benefit most from them. Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers. Existing investors Omega Funds and Longitude Capital also participated. New investors participating in the round include Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, funds managed by Tekla Capital Management LLC, and funds and accounts advised by T. #Monal mehta driversSAN DIEGO, February 07, 2022-( BUSINESS WIRE)- Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners. Three oncology and fibrotic disease programs in clinical development by end of 2022 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |